The Critical Medicines Production Centre (CMPC) is a major pharmaceutical manufacturing facility being developed for API in Alberta, within the Edmonton Research Park. The 83,000 ft² facility forms part of the Canadian Critical Drug Initiative and is intended to strengthen Canada’s domestic capacity to produce essential medicines. Once operational, the CMPC will be capable of producing approximately 73.2 million doses annually and is designed to supply the entire Canadian population with a critical product within 100 days, significantly enhancing national health security and supply-chain resilience.
Key challenges
This state-of-the-art facility includes advanced manufacturing and support spaces such as research and development laboratories, warehousing and specialized process utilities including water for injection, pure steam and inert gas systems. The design also includes a Grade C cleanroom (a controlled environment for solution preparation and packaging) and a Grade D cleanroom (a less critical controlled environment used for non-sterile product preparation). Both require HEPA filtration and bacterial particle monitoring systems.
Innovative solutions
In addition to meeting stringent pharmaceutical and regulatory requirements, the project is targeting LEED Silver certification, reflecting a strong emphasis on sustainability and energy-efficient design.
CIMA+ is providing mechanical systems design, sustainability design and LEED consulting services for the project, delivering its scope under a design-bid-build delivery model. Through these services, CIMA+ plays a key role in ensuring the facility’s complex mechanical and process systems meet operational, regulatory and sustainability objectives from design through construction and commissioning.